Be part of our community by subscribing to our newsletters! Follow the steps below.

1. Subscribe to our Announcement Newsletter. You will receive our news about what do you need to know about our work and the resources available for you. You need to confirm your subscription by email (check your email box and confirm your subscription)

2. Choose your favorite writer. We constantly look for the top minds on the pharmaceutical marketing industry. You can subscribe to their article on their pages and receive every article on your inbox. 

3. Choose the Newsletter that better fits you needs. We recommend the Editor’s pick to receive everything you need to know in one weekly email. 

4. All our newsletters needs to be confirmed by email. After you subscribe on our webpage, you will receive an email asking for your confirmation by clicking a link. Click that link if you want to receive the newsletter. If you don’t receive the email, check your spam box and add our email to your safe sender list. If you address belongs to a company, you may need to forward your confirmation email to your tech department to ask them to add our domain to your company safe sender list. 

You can start here by subscribing to our main Newsletter. Confirm your subscription by clicking CONFIRM on the email you will receive after complete the subscription form.

Don’t forget to check for our other newsletters! Check this page for several options we have for all our users!

NEWSLETTER ANNOUCEMENTS

TPMG FEATURED WRITER NEWSLETTER

- Advertisement -

Top 10 things to consider when designing hybrid meetings

Although the Omicron variant of COVID-19 might have set back the full return to in-person meetings for now, there is no doubt that the future is hybrid. At Impetus Digital, we are slowly seeing more people inquire about our hybrid offerings and how to combine our virtual tools with...

Importance of Diversity in Pharma and Clinical Trials

A version of this article was previously published on PharmaPhorum. “Diversity.” It’s a word that is very commonly thrown around right now, not just in Pharma and healthcare but across all industries. No matter which sector you work in, diversity and inclusion should not be treated as mere buzzwords designed...

Virtual collaboration tools to reduce “digital overload”

A version of this article was previously published in the Journal of mHealth. The COVID-19 pandemic has substantially altered the ways we work, connect with family and friends, and attend meetings and events. By now, “Zoom fatigue”–i.e., tiredness, anxiety, or worry resulting from overusing Zoom and other synchronous virtual platforms–and “digital...

Digital technologies: Pharma’s answer to achieving net zero emissions?

A version of this article was previously published in the Journal of mHealth. As I wrote about earlier this year, it is clear that the climate crisis is no longer something for future generations to worry about, it’s already here and requires our urgent and undivided attention. The Pacific Northwest...

Natalie Yeadon´s Newsletter

- Advertisement -

Top 10 things to consider when designing hybrid meetings

Although the Omicron variant of COVID-19 might have set back the full return to in-person meetings for now, there is no doubt that the future is hybrid. At Impetus Digital, we are slowly seeing more people inquire about our hybrid offerings and how to combine our virtual tools with...

Importance of Diversity in Pharma and Clinical Trials

A version of this article was previously published on PharmaPhorum. “Diversity.” It’s a word that is very commonly thrown around right now, not just in Pharma and healthcare but across all industries. No matter which sector you work in, diversity and inclusion should not be treated as mere buzzwords designed...

Virtual collaboration tools to reduce “digital overload”

A version of this article was previously published in the Journal of mHealth. The COVID-19 pandemic has substantially altered the ways we work, connect with family and friends, and attend meetings and events. By now, “Zoom fatigue”–i.e., tiredness, anxiety, or worry resulting from overusing Zoom and other synchronous virtual platforms–and “digital...

Digital technologies: Pharma’s answer to achieving net zero emissions?

A version of this article was previously published in the Journal of mHealth. As I wrote about earlier this year, it is clear that the climate crisis is no longer something for future generations to worry about, it’s already here and requires our urgent and undivided attention. The Pacific Northwest...

EDITOR´S PICK

- Advertisement -

Clinical Study Suggests SaNOtize Nitric Oxide Nasal Spray Is...

VANCOUVER, British Columbia--(BUSINESS WIRE)--SaNOtize Research and Development (“SaNOtize”) today announced results from a retrospective clinical study assessing the efficacy of nitric oxide releasing nasal spray (NONS™) in preventing COVID-19 infection after high-risk exposure. Nitric oxide is a naturally occurring molecule known to have antimicrobial properties, including a direct effect...

Aro Biotherapeutics to Present New Preclinical Data Highlighting the...

PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced upcoming data presentations highlighting the therapeutic potential of its proprietary Centyrin-siRNA conjugate therapies for the treatment of Pompe disease. During the TIDES USA 2022 meeting taking place in Boston from May 9 to 12,...

Biotech Partnership to Accelerate Understanding of Genetics of Long...

OXFORD, England--(BUSINESS WIRE)--PrecisionLife Limited, a global techbio company using its deep insights into disease biology and patient stratification to drive precision medicine in chronic diseases, is pleased to announce a partnership with Sano Genetics, a genetic research platform enabling patients to participate in ethical research projects, to advance understanding...

Cybin and Kernel Announce Results from Kernel Flow® Piloting...

LOS ANGELES & TORONTO--(BUSINESS WIRE)--Kernel, a leader in non-invasive neuroimaging, and Cybin Inc. (NEO:CYBN) (NYSE American:CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™,” are pleased to announce pilot results from a Cybin-sponsored feasibility study evaluating Kernel’s quantitative neuroimaging technology, Flow, to measure cortical hemodynamics while experiencing an...

LOOK WHO IS ON THE MOVE!

Seagen Announces Resignation of President, Chairman & CEO Clay...

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that the Board of Directors yesterday accepted the resignation of Clay Siegall, Ph.D., as President, CEO and member of the Board of Directors. Felix J. Baker, Ph.D., formerly Lead Independent Director, has been appointed Chair of the Board of Directors. Roger...

Doug Drysdale and Dr. Shaheen Lakhan Join SpineThera Board

PLYMOUTH, Minn.--(BUSINESS WIRE)--SpineThera, Inc., a privately held, clinical stage pharmaceutical company focused on the development of SX600 (a novel formulation of sustained-release dexamethasone for treatment of sciatica) announced today that biopharma executive Doug Drysdale and physician-scientist Dr. Shaheen Lakhan have joined SpineThera’s board of directors to support the further...

PharmaEssentia Announces Appointment of Meredith Manning to President of...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced the appointment of Meredith Manning to President of the Americas, effective immediately. “PharmaEssentia has continued to build momentum with...

Avilar Therapeutics Announces Formation of Scientific Advisory Board With...

WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the formation of its Scientific Advisory Board (SAB) comprised of an esteemed group of leading scientists with expertise in protein degradation, chemistry, genetics, and drug discovery. The Avilar SAB will provide guidance to the company...

INDUSTRY NEWS

- Advertisement -

ReCode Therapeutics Presents Preclinical Data from Inhaled mRNA Therapeutic...

MENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)--ReCode Therapeutics, a biopharmaceutical company powering the next wave of genetic medicines through superior delivery today presented new preclinical data from the company’s inhaled mRNA-based molecular therapy program for the treatment of primary ciliary dyskinesia (PCD) in three posters at the American Thoracic Society...

Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study...

REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, today announced positive top-line results from a pharmacokinetic (PK) study for AVT04, Alvotech’s proposed biosimilar to Stelara® (ustekinumab). The PK similarity study (AVT04-GL-101) utilized a single dose,...

Ontada Research Highlights Power of Real-World Oncology Data at...

IRVING, Texas--(BUSINESS WIRE)--Ontada®, a McKesson business focused on provider technology and actionable real-world research, education and evidence in oncology, announced the acceptance of seven abstracts for presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The leading global conference for health economics and outcomes research, ISPOR 2022...

Blue Earth Diagnostics Announces Additional Results from Phase 3...

BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced results of additional endpoints from its Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer. Results reporting the impact of 18F-rhPSMA-7.3 PET on...

REGULATORY AFFAIRS

Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to...

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces the Company will submit an amended...

Horizon Therapeutics plc Receives European Commission (EC) Approval of...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the European Commission (EC) approval of UPLIZNA® (inebilizumab) as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+), following the positive opinion adopted by the Committee for Medicinal Products for...

VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™,...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the European Commission (EC) has granted Marketing Authorisation for PreHevbri™ for active immunisation against infection caused by all known subtypes of...

PharmaCyte Biotech Updates Status of Investigational New Drug Application...

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today provided an update on PharmaCyte’s activities to lift the U.S. Food and Drug Administration’s (FDA) clinical hold on PharmaCyte’s treatment for locally...
Get a free copy of "Cracking the Generics Code"

Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.